Eugia Pharma Specialities Ltd receives OAI classification from USFDA for Unit 2

The United States Food and Drug Administration (US FDA) inspected Unit-II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company, situated at RIICO Industrial Area, Phase-III, Bhiwadi, 301 019, Rajasthan, from November 03 to November 14, 2025. At the end of the inspection, a 'Form 483' was issued with 09 observations.

Subsequently, US FDA has now determined the inspection classification status of this unit as 'Official Action Indicated' (OAI).

At this point in time, the Company doesn't foresee any impact on the business. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1287.40 as compared to the previous close of Rs. 1279.35. The total number of shares traded during the day was 13913 in over 1155 trades.

The stock hit an intraday high of Rs. 1299.75 and intraday low of 1275.50. The net turnover during the day was Rs. 17905734.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals EugiaPharmaSpecialities USFDa OAI Unit2